| Symbol | KALY |
|---|---|
| Name | KALI, INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | 75225 United States TX 8300 Douglas Ave,. Sutie 800 |
| Telephone | 214-210-0459 |
| Fax | — |
| — | |
| Website | http://www.kali-extracts.com |
| Incorporation | US |
| Incorporated On | 2006 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | — |
| Audit Status | UNAUDITED |
| Reporting Status | Dark: Alternative Reporting Standard |
| CIK | 0001388311 |
| Description | On November 15, 2018, Kali, Inc announced the acquisition of NCM Biotech which is the developer and owner of a patented botanical extraction process - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING ..." With the patented intellectual property (IP), to include the existing and ongoing research and development acquired from NCM Biotech, Kali now focuses on the development of pharmaceuticals to treat various illnesses, diseases and chronic pain as a symptom of various diagnoses. Kali also concentrates on the development of health and wellness therapies. Additional info from OTC: |
No news found.